Trillium Therapeutics Inc (TRIL)

[jondoeuk]

This paper is a summary of 621 data that has already presented. It provides the justification of dose escalation beyond the 0.2 mg level. CD47 receptor occupancy was 34.4% at the 0.2 mg dosages, but jumped to 58.3%, 62.5% and 66.1% at 0.3mg, 0.4mg and 0.5mg, respectively https://clincancerres.aacrjournals.org/content/early/2021/02/19/1078-0432.CCR-20-3706

The trial is continuing with higher dosages.